Publication | Open Access
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
18
Citations
15
References
2023
Year
Ascendis Pharma, A/S.
| Year | Citations | |
|---|---|---|
Page 1
Page 1